Pudexacianinium chloride

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Laparoscopic/Minimally Invasive Colorectal Surgery

Conditions

Laparoscopic/Minimally Invasive Colorectal Surgery

Trial Timeline

Oct 6, 2020 → Nov 29, 2021

NCT ID

NCT04238481

About Pudexacianinium chloride

Pudexacianinium chloride is a phase 2 stage product being developed by Astellas Pharma for Laparoscopic/Minimally Invasive Colorectal Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT04238481. Target conditions include Laparoscopic/Minimally Invasive Colorectal Surgery.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05999747	Phase 3	Completed	Mar 19, 2024	Oct 13, 2025	Intraoperative Ureter Visualization
NCT05754333	Phase 3	Completed	Aug 2, 2023	Jan 16, 2025	Intraoperative Ureter Visualization
NCT05495581	Phase 1	Completed	Aug 25, 2022	May 8, 2023	Healthy Volunteers
NCT05457842	Phase 2	Terminated	Aug 10, 2022	Sep 20, 2022	Sentinel Lymph Node Biopsy
NCT04238481	Phase 2	Completed	Oct 6, 2020	Nov 29, 2021	Laparoscopic/Minimally Invasive Colorectal Surgery

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved